Inhibrx’s OX40 Combo Nearly Doubles Responses — Investors Focused on the HPV Catch
First randomized OX40 agonist win in HNSCC still sparked a selloff. Investors questioned how broad the commercial opportunity really is.
/ 5 items
#INBX↓
INBRX-106 + Keytruda Nearly Doubles Response Rate in First-Line Head & Neck Cancer
Inhibrx drug INBRX-106 with pembrolizumab boosted tumor response in head/neck cancer, showing higher shrinkage and immune activation.
$8 Billion Opportunity: Inhibrx’s Experimental Cancer Drug Draws Major Interest
Inhibrx is drawing strong interest from Merck and other big pharma for its experimental cancer drug INBRX-106 that could boost Keytruda. Potential $9B spin-off value.
Wall Street Goes Bullish on Two Biotech Stocks: INBX and MPLT
Stifel & Needham back INBX & MPLT: promising cancer & brain drugs, strong safety, big market potential.
Ozekibart Achieves Primary Endpoint in Chondrosarcoma, Showing Strong Efficacy and Safety Results
Clinical trial results show Inhibrx’s Ozekibart significantly improves survival measures in advanced chondrosarcoma, where no approved options exist, and demonstrates encouraging high response rates in colorectal cancer and Ewing sarcoma.